Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
The company had recorded a loss of $1.22 per share in the year-ago quarter. Total revenues, comprising license and collaboration revenues, came in at $14.3 million in the third quarter compared with $17.2 million reported in the year-ago period. The top line missed the Zacks Consensus Estimate of $15 million. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Research and development expenses were $94.3 million in the third quarter, down almost 5.8% from the year-ago quarter's level. General and administrative expenses totaled $26.5 million, increasing around 4.3% year over year. As of Sept 30, 2024, BEAM had cash, cash equivalents and marketable securities worth $925.8 million compared with $1.2 billion as of June 30, 2024. The company expects that its existing cash balance is likely to fund its operating expenses into 2027. Year to date, shares of Beam Therapeutics have declined 12% compared with the industry's decrease of 3.8%. Image Source: Zac
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceGlobeNewswire
- Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 11/5/24 - Miss
BEAM
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form 4
- 11/8/24 - Form SC
- BEAM's page on the SEC website